Literature DB >> 9038718

Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia.

C Szabó1, G Haskó, B Zingarelli, Z H Németh, A L Salzman, V Kvetan, S M Pastores, E S Vizi.   

Abstract

Pro-inflammatory cytokines, such as tumour necrosis factor (TNF) and free radicals, such as nitric oxide (NO), are mediators of endotoxaemia. Catecholamines are in clinical use to treat the haemodynamic consequences of severe septic shock. Beta-adrenergic agonists exert many of their effects by elevation of intracellular cyclic AMP (cAMP) concentration. Cyclic AMP can modulate endotoxin-induced cytokine and NO production. Here we investigate the effect of isoproterenol pretreatment on the cytokine and NO production induced by bacterial lipopolysaccharide (LPS, 4-10 mg/kg). Pretreatment with isoproterenol (10 mg/kg) blunted the LPS-induced TNF response, increased the LPS-induced formation of interleukin-10 and interleukin-6 and reduced the LPS-induced production of NO in conscious mice. In anaesthetized rats, pretreatment with isoproterenol prevented the LPS-induced suppression of vascular contractility to norepinephrine in the thoracic aorta ex vivo. The hyporeactivity is due to expression of the inducible isoform of NO synthase (iNOS) and was restored by in vitro administration of NG-methyl-L-arginine (L-NMA), an inhibitor of NO synthase. However, L-NMA did not alter vascular contractility in control vessels or in rings taken from the LPS-treated rats pretreated with isoproterenol. Our findings suggest that, in addition to its haemodynamic actions, isoproterenol may also exert beneficial effects by modulating the endotoxin-induced inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9038718      PMCID: PMC1456713          DOI: 10.1046/j.1365-2567.1997.00137.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  30 in total

1.  Differential regulatory effects of adenosine on cytokine release by activated human monocytes.

Authors:  M G Bouma; R K Stad; F A van den Wildenberg; W A Buurman
Journal:  J Immunol       Date:  1994-11-01       Impact factor: 5.422

2.  Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs.

Authors:  C Platzer; C Meisel; K Vogt; M Platzer; H D Volk
Journal:  Int Immunol       Date:  1995-04       Impact factor: 4.823

3.  Peroxynitrite-mediated oxidation of dihydrorhodamine 123 occurs in early stages of endotoxic and hemorrhagic shock and ischemia-reperfusion injury.

Authors:  C Szabó; A L Salzman; H Ischiropoulos
Journal:  FEBS Lett       Date:  1995-09-25       Impact factor: 4.124

4.  Cyclic AMP-elevating agents induce an inducible type of nitric oxide synthase in cultured vascular smooth muscle cells. Synergism with the induction elicited by inflammatory cytokines.

Authors:  M Koide; Y Kawahara; I Nakayama; T Tsuda; M Yokoyama
Journal:  J Biol Chem       Date:  1993-11-25       Impact factor: 5.157

5.  Effects of a nitric oxide synthase inhibitor in humans with septic shock.

Authors:  A Petros; G Lamb; A Leone; S Moncada; D Bennett; P Vallance
Journal:  Cardiovasc Res       Date:  1994-01       Impact factor: 10.787

6.  Activation of soluble guanylyl cyclase by a factor other than nitric oxide or carbon monoxide contributes to the vascular hyporeactivity to vasoconstrictor agents in the aorta of rats treated with endotoxin.

Authors:  C C Wu; C Szabó; S J Chen; C Thiemermann; J R Vane
Journal:  Biochem Biophys Res Commun       Date:  1994-05-30       Impact factor: 3.575

7.  Differential effect of selective block of alpha 2-adrenoreceptors on plasma levels of tumour necrosis factor-alpha, interleukin-6 and corticosterone induced by bacterial lipopolysaccharide in mice.

Authors:  G Haskó; I J Elenkov; V Kvetan; E S Vizi
Journal:  J Endocrinol       Date:  1995-03       Impact factor: 4.286

8.  NG-methyl-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogs.

Authors:  R G Kilbourn; D M Cromeens; F D Chelly; O W Griffith
Journal:  Crit Care Med       Date:  1994-11       Impact factor: 7.598

9.  Regulation of macrophage-derived tumor necrosis factor production by modification of adrenergic receptor sensitivity.

Authors:  T A Ignatowski; R N Spengler
Journal:  J Neuroimmunol       Date:  1995-08       Impact factor: 3.478

10.  Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2.

Authors:  G Strassmann; V Patil-Koota; F Finkelman; M Fong; T Kambayashi
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more
  24 in total

Review 1.  Present concepts on the inflammatory modulators with special reference to cytokines.

Authors:  A S J P A M Van Miert
Journal:  Vet Res Commun       Date:  2002-02       Impact factor: 2.459

Review 2.  Receptor-mediated interaction between the sympathetic nervous system and immune system in inflammation.

Authors:  G Haskó
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

Review 3.  The effects of acute psychological stress on circulating and stimulated inflammatory markers: A systematic review and meta-analysis.

Authors:  Anna L Marsland; Catherine Walsh; Kimberly Lockwood; Neha A John-Henderson
Journal:  Brain Behav Immun       Date:  2017-01-12       Impact factor: 7.217

4.  The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.

Authors:  Akbar Ahmad; Gabor Olah; David N Herndon; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-05       Impact factor: 8.739

Review 5.  Sympathetic modulation of immunity: relevance to disease.

Authors:  Denise L Bellinger; Brooke A Millar; Sam Perez; Jeff Carter; Carlo Wood; Srinivasan ThyagaRajan; Christine Molinaro; Cheri Lubahn; Dianne Lorton
Journal:  Cell Immunol       Date:  2008-03-04       Impact factor: 4.868

6.  Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Paul E Polak; Sergey Kalinin; Douglas L Feinstein
Journal:  Brain       Date:  2011-02-04       Impact factor: 13.501

Review 7.  Use of inotropes and vasopressor agents in critically ill patients.

Authors:  Mansoor N Bangash; Ming-Li Kong; Rupert M Pearse
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

8.  The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease.

Authors:  Sergey Kalinin; Paul E Polak; Shao Xia Lin; Amul J Sakharkar; Subhash C Pandey; Douglas L Feinstein
Journal:  Neurobiol Aging       Date:  2011-06-25       Impact factor: 4.673

Review 9.  Locus Coeruleus Modulates Neuroinflammation in Parkinsonism and Dementia.

Authors:  Filippo Sean Giorgi; Francesca Biagioni; Alessandro Galgani; Nicola Pavese; Gloria Lazzeri; Francesco Fornai
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923

10.  Stress in the adult rat exacerbates muscle pain induced by early-life stress.

Authors:  Pedro Alvarez; Paul G Green; Jon D Levine
Journal:  Biol Psychiatry       Date:  2013-05-21       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.